Advertisement
Screener

Disc Medicine, Inc. (IRON) P/E Ratio

2.8 / 5 stars · 68/120 Roast Me

Disc Medicine, Inc. PE Ratio

The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.

  • Disc Medicine, Inc. pe ratio for the quarter ending 2026-06-30 was -11.4, a change of 1.23 year-over-year.
  • Disc Medicine, Inc. pe ratio for the quarter ending 2026-03-31 was -10.11, a change of 4.62 year-over-year.
  • Disc Medicine, Inc. pe ratio for the quarter ending 2025-12-31 was -14.18, a change of 3.13 year-over-year.
  • Disc Medicine, Inc. pe ratio for the quarter ending 2025-09-30 was -12.77, a change of 1.36 year-over-year.
  • Disc Medicine, Inc. pe ratio for fiscal 2026 was -11.4.
  • Disc Medicine, Inc. pe ratio for fiscal 2025 was -14.18, a change of 3.13 from fiscal 2024.
  • Disc Medicine, Inc. pe ratio for fiscal 2024 was -17.31, a change of 1.1 from fiscal 2023.
  • Disc Medicine, Inc. pe ratio for fiscal 2023 was -18.41, a change of -11.02 from fiscal 2022.
Available history
2020-12-31 to 2026-06-30
Data captured

Historical PE Ratio

DatePE RatioMarket capitalizationNet income 12 month
2026-06-30-11.4$2.8B-$245.89M
2026-03-31-10.11$2.44B-$241.6M
2025-12-31-14.18$3.01B-$212.18M
2025-09-30-12.77$2.31B-$181.11M
2025-06-30-12.63$1.84B-$145.39M
2025-03-31-14.74$1.72B-$116.49M
2024-12-31-17.31$1.89B-$109.36M
2024-09-30-14.13$1.46B-$103.48M
2024-06-30-14.71$1.34B-$91M
2024-03-31-19.08$1.54B-$80.6M
2023-12-31-18.41$1.41B-$76.43M
2023-09-30-17.69$1.13B-$64.09M
2023-06-30-15.34$1.01B-$66.12M
2023-03-31-6.94$414.8M-$59.76M
2022-12-31-7.39$346.15M-$46.83M
2022-09-30-121.69$2.13B-$17.51M
2022-06-30-110.14$2.19B-$19.91M
2022-03-31-67.33$1.8B-$26.77M
2021-12-31-2.21$79.39M-$35.97M
2021-09-30-76.44$5.23B-$68.36M
2021-06-30-139.72$8.36B-$59.81M
2021-03-31-348.64$17.48B-$50.14M
2020-12-31-125.78$5.14B-$40.84M

Annual PE Ratio

DatePE RatioMarket capitalizationNet income 12 month
2026-06-30-11.4$2.8B-$245.89M
2025-12-31-14.18$3.01B-$212.18M
2024-12-31-17.31$1.89B-$109.36M
2023-12-31-18.41$1.41B-$76.43M
2022-12-31-7.39$346.15M-$46.83M
2021-12-31-2.21$79.39M-$35.97M
2020-12-31-125.78$5.14B-$40.84M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Immunome Inc. (IMNM)United States$2.538B-9.45
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
uniQure N.V. (QURE)$2.416B-4.93
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67
NewAmsterdam Pharma Co N.V. (NAMS)$2.719B-15.37
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82